The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Reference |
|---|
| "The selectivity of proteinuria is most frequently decreased, especially in the advanced stages of diabetic nephropathy." | ( Astrug, A; Genov, D, 1978) |
| "Tubular proteinuria is generally accepted as the critical effect following long-term, low-level exposure to cadmium as seen in an industrial environment." | ( Kazantzis, G, 1979) |
| "Tubular proteinurias are found in inflammatory, degenerative and vascular tubulopathies." | ( Boesken, WH, 1975) |
| "This proteinuria is partly due to an increased excretion of higher molecular weight proteins, which could be identified as deriving from plasma." | ( Galaske, RG; Gärtner, K; Stolte, H, 1975) |
| "Microproteinuria is an early sign of clinical diabetic nephropathy, and it also has the power to predict cardiovascular mortality in both types of diabetes." | ( Debán Miguel, C; Dutu, AL; Häncu, N; Lobón Cerviá, C; Mösler, R; Suciu, I; Veresiu, IA; Villar, A; Zurro Hernández, J, 1991) |
| "Exercise-induced proteinuria is of the mixed glomerular-tubular type and has been thought to be due to increased glomerular permeability to macromolecular proteins in response to activation of the renin-angiotensin system and catecholamines and a reduction in renal hemodynamics." | ( Ikawa, S; Suzuki, M, 1991) |
| "We conclude that proteinuria is decreased on non-prednisone days in patients with membranous glomerulonephritis treated with alternate-day steroids." | ( Hoitsma, AJ; Koene, RA; Wetzels, JF, 1990) |
| "In the first phase, proteinuria is non-selective with IgG clearance equal to or exceeding transferrin or albumin clearance." | ( Allen, TJ; Cooper, ME; Jerums, G, 1989) |
| "Proteinuria is a major manifestation of glomerular disease (glomerulonephritis, GN)." | ( Baricos, WH; Cortez, SL; O'Connor, SE; Shah, SV; Wu, LT, 1988) |
| "Proteinuria is the clinical hallmark of diabetic nephropathy and the harbinger of progressive renal disease." | ( Conger, JD; Falk, SA; Hammond, WS; Harris, DC; Schrier, RW, 1988) |
| "This proteinuria is generally reversible, when light chains no longer appear in the urine." | ( Cooper, EH; Crockson, RA; Forbes, MA; MacLennan, IC, 1984) |
| "Proteinuria is a side effect of captopril treatment in hypertensive patients." | ( Brown, AD; Chiu, PJ, 1981) |
| "Nephrotic range proteinuria is uncommon in patients with IgA nephritis." | ( Katz, A; Landy, PJ; Walker, JF, 1983) |
| "The proteinuria is predominantly of glomerular origin, but some is also of tubular origin." | ( Broch, H; Hovig, T; Imerslund, O; Monn, E; Seip, M, 1984) |
| "This form of proteinuria is probably associated with a genuine toxaemia of pregnancy." | ( Boesken, WH; Kaltenbach, FJ; Quaas, L; Toussaint, MN; Wilhelm, C; Ziupa, J, 1983) |
| "Proteinuria is the most frequent sign in the early stage of the amyloidosis." | ( Michels, H; Renaud, M; Renz, K; Schuchmann, L, 1981) |
| "Proteinuria is associated with increased cardiovascular morbidity and mortality." | ( Chang, PC; Joles, JA; Koomans, HA; Rabelink, TJ; Stroes, ES, 1995) |
| "In conclusion, proteinuria is a common, important, and rather non-specific risk factor for increased morbidity and mortality in diabetes." | ( Fuller, JH; Kenny, S; Lee, E; Stephenson, JM; Stevens, LK, 1995) |
| "Overt proteinuria is often accompanied by hypercholesterolemia and is associated with increased lipoprotein(a) levels." | ( Batlle, D; Keilani, T; Schlueter, W, 1995) |
| "Postexercise proteinuria is directly related to the intensity of exercise rather than to its duration." | ( Poortmans, JR; Vanderstraeten, J, 1994) |
| "Screening for proteinuria is widely recommended in the monitoring of pregnancy in order to detect preeclampsia." | ( Bouvier, P; Mauris, A; Robert, CF; Rougemont, A, 1995) |
| "Because clinical proteinuria is associated with a high frequency of cardiovascular disease, and because microalbuminuria predicts the development of renal and cardiovascular disease in diabetes, we investigated whether serum sialic acid levels are increased in insulin-dependent diabetes mellitus (IDDM) patients with microalbuminuria or clinical proteinuria." | ( Crook, MA; Earle, K; Morocutti, A; Pickup, JC; Viberti, G; Yip, J, 1994) |
| "Proteinuria is the primary manifestation of a variety of glomerular diseases which are characterized clinically by the nephrotic syndrome." | ( Hutchison, FN, 1993) |
| "Significant proteinuria is a common finding and proteinuria within the nephrotic range does occur." | ( Burden, RP; Davison, AM; Innes, A; Johnston, PA; Morgan, AG, 1993) |
| "Proteinuria is an important indicator of renal disease and the types of proteins found in the urine help distinguish glomerular and tubular disorders." | ( Geyer, SJ, 1993) |
| "Proteinuria is noted among 33% of all patients but 20% in group 1 and 2 versus 70% in group 3." | ( Boussinesq, M; Chippaux, JP; Ducorps, M; Gardon, J; Gardon-Wendel, N; Ndong, W; Ranque, S; Schneider, D, 1995) |
| "The main cause of proteinuria is likely to be depletion of negative charge on the GBM in SRNS, and distortion of capillary pore size in MGN and MPGN, with probable overlap of these mechanisms in each disease, especially in FGS." | ( Adhikari, M; Coovadia, HM; Ramjee, G, 1996) |
| "The cause of the proteinuria is unknown but kidney damage due to severe Cbl deficiency and an error in a multiligand renal receptor are among the possibilities." | ( Gräsbeck, R, 1997) |
| "Heavy proteinuria is associated with marked abnormalities of lipoprotein metabolism and increased risk of atherogenesis." | ( Boulton-Jones, JM; Caslake, MJ; Deighan, CJ; McConnell, M; Packard, CJ, 1998) |
| "Proteinuria is a well known risk factor for cardiovascular morbidity." | ( Jayaraman, M; Mathai, T; Ramachandran, A; Snehalatha, C; Viswanatham, V, 1998) |
| "Proteinuria is observed in 10% of the patients, often secondary to extramembranous glomerulopathy." | ( Bridoux, F; Ducq, P; Gheerbrant, JD; Kyndt, X; Makdassi, R; Reumaux, D; Vanhille, P, 1999) |
| "Proteinuria is a marker for diabetic nephropathy and potentially a surrogate marker for advanced atherosclerosis." | ( Ellis, SG; Franco, I; Marso, SP; Raymond, RE; Topol, EJ; Tuzcu, M; Whitlow, PL, 1999) |
| "The presence of proteinuria is the key determinant of risk following PCI for diabetics." | ( Ellis, SG; Franco, I; Marso, SP; Raymond, RE; Topol, EJ; Tuzcu, M; Whitlow, PL, 1999) |
| "Proteinuria is currently considered a very sensitive predictor of diabetic nephropathy, but 20-25% of all diabetic patients with negative Albustix reaction excrete higher than normal (< 20 mg/24 h) amounts of albumin in their urine." | ( DeFronzo, RA; Kudolo, GB, 1999) |
| "Proteinuria is associated with a progressive loss of renal function; we recently found that both intrarenal effects of proteinuria and the state of systemic nephrosis play an independent role in proteinuria-induced renal damage." | ( de Boer, E; de Jong, PE; de Zeeuw, D; Navis, G; Wapstra, FH, 1999) |
| "The term "tubular proteinuria" is often used interchangeably with "low molecular weight proteinuria" (LMWP), although the former implies a definite etiology." | ( Deschodt-Lanckman, MM; Lapsley, M; Norden, AG; Nortier, JL; Scheinman, SJ; Thakker, RV; Unwin, RJ; Wrong, O, 2000) |
| "Reduction of proteinuria is a prerequisite for successful long-term renoprotection." | ( Andersen, S; Bos, H; De Jong, PE; De Zeeuw, D; Navis, G; Parving, HH; Rossing, P, 2000) |
| "Proteinuria is now accepted to be not just a sign of renal disease but also a contributory factor to the development of progressive tubulointerstitial fibrosis." | ( Gallagher, H; Newman, DJ; Thakkar, H, 2000) |
| "Clinical proteinuria is a risk factor for both end-stage renal disease and cardiovascular disease." | ( Capes, SE; Gerstein, HC; Negassa, A; Yusuf, S, 2000) |
| "Clinical proteinuria is an independent predictor of hospitalization for CHF and mortality in diabetic and nondiabetic patients with LV dysfunction." | ( Capes, SE; Gerstein, HC; Negassa, A; Yusuf, S, 2000) |
| "Proteinuria is a significant, although relatively weak, risk factor for all-cause mortality in men and women, and for cardiovascular disease mortality in women." | ( Culleton, BF; Kannel, WB; Larson, MG; Levy, D; Parfrey, PS, 2000) |
| "Blood pressure and proteinuria are important determinants of progressive renal failure in patients with renal diseases." | ( Huysmans, FT; Wetzels, JF, 2000) |
| "Proteinuria is usually considered a manifestation of glomerular disease." | ( Du Cailar, G; Halimi, JM; Mimran, A; Ribstein, J, 2000) |
| "To the extent that proteinuria is an important determinant of progression, reduction of proteinuria would result in retardation of progression." | ( Shah, S, 2001) |
| "Proteinuria is one of the major risk factors for renal disease progression in patients with chronic nephropathies." | ( Benigni, A; Perico, N; Remuzzi, G, 2001) |
| "Postexercise proteinuria is a common phenomenon depending on hypothetical mechanisms such as the hemodynamic system and its sympathetic component." | ( Haggenmacher, C; Poortmans, JR; Vanderstraeten, J, 2001) |
| "The severity of proteinuria is the main predictive factor in the progression of renal failure in chronic nephropathies." | ( Dall'Anese, C; García de Vinuesa, S; Gómez-Campderá, F; Luño, J; Ridao, N; Sánchez, M; Valderrábano, F, 2001) |
| "Tubular proteinuria is an extra-intestinal manifestation of inflammatory bowel disease irrespective of 5-ASA treatment." | ( Fraser, JS; Lamb, EJ; Muller, AF; Newman, DJ; Smith, DJ, 2001) |
| "Prolonged proteinuria is a risk factor for renal damage." | ( Camacho Díaz, JA; García García, L; Giménez Llort, A; Jiménez González, R, 2001) |
| "Proteinuria is frequently encountered in patients in the intensive care unit, most likely as a result of renal tubular cell injury." | ( Branten, AJ; Klasen, IS; ten Dam, MA; Wetzels, JF, 2001) |
| "However, residual proteinuria is often present." | ( Bos, H; De Jong, PE; De Zeeuw, D; Henning, RH; Navis, G, 2002) |
| "Dipstick test for proteinuria is widely available, but no information on its sensitivity or specificity is available when implementing current guidelines." | ( Agarwal, R; Lewis, RR; Panesar, A, 2002) |
| "Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality." | ( Lee, TM; Su, SF; Tsai, CH, 2002) |
| "Proteinuria is a risks factor that accelerates the progression of renal insufficiency by several mechanisms." | ( Franco, A; Jiménez del Cerro, LA; Olivares, J, 2002) |
| "Proteinuria is an indicator of renal disease." | ( Christophersen, B; Fauchald, P; Hartmann, A; Henriksen, T; Jenssen, T; Midtvedt, K; Monn, E; Reisaeter, AV, 2002) |
| "Proteinuria is a poor prognostic feature for various types of glomerular disease and its toxic action may be related to the activation of tubular epithelial cells towards increased production of cytokines and chemoattractant peptides." | ( Alexandri, S; El Nahas, AM; Goumenos, DS; Kalliakmani, P; Oldroyd, S; Tsakas, S; Vlachojannis, JG, 2002) |
| "Proteinuria is "nephrotoxic" and leads to glomerular and tubulo-interstitial lesions." | ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "The values of proteinuria are illustrated in Graph I." | ( Arandjelović, S; Bogić, M; Bolpacić, J; Jovicić, Z; Perić-Popadić, A; Rasković, S; Stefanović, L; Tomić-Spirić, V, 2002) |
| "Proteinuria is the single most powerful predictor of ESRD in patients with type 2 diabetes and nephropathy." | ( Keane, WF; Lyle, PA, 2003) |
| "Proteinuria is an important marker of kidney disease." | ( Butani, L; Larson, TS; Morgenstern, BZ; Wilson, DM; Wollan, P, 2003) |
| "Nevertheless when proteinuria is present it disappears." | ( Durand, D; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J, 2003) |
| "Reducing proteinuria is renoprotective, particularly in nephrotic patients." | ( Perna, A; Remuzzi, G; Ruggenenti, P, 2003) |
| "Proteinuria is assumed to play a pathogenetic role in progressive renal damage." | ( Bos, H; de Jong, PE; de Zeeuw, D; Henning, RH; Laverman, GD; Navis, G; Tiebosch, AT, 2003) |
| "Exercise-induced proteinuria is a common consequence of physical activity, although its mechanism is not clear." | ( Gündüz, F; Sentürk, UK, 2003) |
| "Proteinuria is a significant independent determinant of the progression of chronic renal diseases." | ( Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F, 2003) |
| "Proteinuria is a major cause of progression in renal disease." | ( Stahl, RA; Wolf, G, 2003) |
| "We conclude that proteinuria is an independent predictor of progression to end-stage renal failure also in children whose renal impairment is due to congenital hypodysplasia." | ( Ardissino, G; Avolio, L; Ciofani, A; Claris-Appiani, A; Daccò, V; Dello Strologo, L; Montini, G; Procaccio, M; Taioli, E; Testa, S; Viganò, S, 2004) |
| "Proteinuria is quantified for diagnostic and prognostic purposes and to assess responses to therapy." | ( Ando, Y; Asano, Y; Kusano, E; Morishita, Y; Muto, S; Nemoto, J; Tanba, K; Umino, T, 2004) |
| "This effect on proteinuria is not related with blood pressure reduction." | ( Arceo-Navarro, A; Gomez-Harper, CT; Lozano-Nuevo, JJ; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2004) |
| "Persistent proteinuria is not only a marker of irreversible glomerular lesions but also a risk factor for tubulointerstitial lesions, which plays a significant role in progression into ESRD." | ( Saito, T, 2004) |
| "Heavy proteinuria is common after the use of sirolimus as rescue therapy in children with renal Tx." | ( Butani, L, 2004) |
| "A persistent proteinuria is commonly observed in nephrotic patient with focal segmental glomerulosclerosis (FSGS) under treatment with prednisolone+/-cyclophosphamide or with vasodilators (ACEI+AII receptor antagonist, calcium channel blocker and antiplatelet agent)." | ( Butthep, P; Futrakul, N; Futrakul, P; Jetanalin, P; Panichakul, T; Patumraj, S; Siriviriyakul, P, 2004) |
| "If proteinuria is of sufficient amount, and persists for long enough, then a series of consequences arises which is called the nephrotic syndrome." | ( Henschkowski, J; Klein, M; Vogt, B; Yu, Z, 2004) |
| "Proteinuria is a significant problem in medicine today, although glomerular events underlying it are unknown." | ( McCarthy, ET; Sharma, M; Sharma, R, 2005) |
| "The proteinuria is frequently the initial insult to the kidney and it usually followed by a progressive decline in the glomerular filtration rate." | ( Canepa, C; De Reyes, V; Dieguez, SM; Liern, M; Vallejos, G, 2004) |
| "Baseline proteinuria is an important risk factor for kidney failure and provides a means to identify patients at greatest risk." | ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| "The magnitude of proteinuria is associated with a graded increase in the risk of progression to end-stage renal disease and cardiovascular events." | ( Bakris, GL; Greene, T; Hebert, L; Lea, J; Lipkowitz, M; Massry, S; Middleton, J; Miller, E; Rostand, SG; Smith, W, 2005) |
| "Proteinuria is a risk factor for progression of chronic renal failure." | ( Andry, C; Bonegio, RG; Fuhro, R; Lieberthal, W; Salant, DJ; Valeri, CR; Wang, Z, 2005) |
| "Sustained proteinuria is a major factor leading to kidney fibrosis and end-stage renal failure." | ( Holmberg, C; Jalanko, H; Karikoski, R; Kuusniemi, AM; Lapatto, R; Rapola, J, 2005) |
| "Proteinuria is recognized as an independent risk factor for cardiovascular and renal disease and as a predictor of end organ damage." | ( Boyd, JC; Newall, RG; Price, CP, 2005) |
| "Proteinuria is a recognized complication of obesity, but the pathogenesis remains unclear." | ( Iwasawa, H; Matsumoto, H; Nagaoka, Y; Nakao, T; Okada, T; Tomaru, R; Wada, T, 2005) |
| "Because proteinuria is a hallmark for kidney disease, we examined the relationship between proteinuria and tubular induction of HO-1, specifically questioning whether increased trafficking of protein across the renal tubular epithelium, as a consequence of proteinuria, induces tubular expression of HO-1." | ( Alam, J; Croatt, AJ; Grande, JP; Murali, NS; Nath, KA; Pedraza-Chaverri, J, 2006) |
| "Proteinuria is a major risk factor for the progression of kidney disease and the development of cardiovascular disease." | ( Appel, LJ; Boulware, LE; Guallar, E; Jee, SH; Miller, ER; Suh, I, 2005) |
| "Proteinuria is a marker of cardiovascular and renal disease in patients with chronic kidney disease (CKD), and reduction in proteinuria has been associated with improved cardiovascular and renal outcomes." | ( Acharya, M; Agarwal, R; Batlle, D; Hippensteel, RL; Melnick, JZ; Qiu, P; Tian, J; Williams, L, 2005) |
| "Microproteinuria is mainly associated with UC and its activity but not affected by 5-ASA." | ( Archimandritis, A; Dandakis, DC; Georgouli, A; Goumas, KE; Panagiotaki, M; Poulou, AC; Soutos, DC; Tyrmpas, I, 2006) |
| "Proteinuria is a common manifestation of renal disease which is a significant cause of morbidity in patients with sickle cell disease (SCD)." | ( Abdella, N; Al Wazzan, H; Kortom, M; Marouf, R; Mojiminiyi, O, 2006) |
| "Proteinuria is associated with age, haemoglobin, and abnormalities of GFR." | ( Abdella, N; Al Wazzan, H; Kortom, M; Marouf, R; Mojiminiyi, O, 2006) |
| "Proteinuria is a non-specific marker of inflammation that may reflect the glomerular component of systemic capillary leak." | ( Beattie, WS; Ghannam, M; Karkouti, K; McCluskey, SA; Shayan, S; Wijeysundera, DN, 2006) |
| "Proteinuria is associated with oxidant stress and inflammation." | ( Acikel, C; Aktug, H; Caglar, K; Eyileten, T; Ikizler, TA; Kaya, A; Korkmaz, A; Oguz, Y; Oter, S; Sonmez, A; Topal, T; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2006) |
| "Proteinuria is both an indicator of renal damage as well as a progression factor for ongoing loss of renal function." | ( Brandenburg, V; Floege, J, 2006) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | ( Remuzzi, G; Ruggenenti, P, 2006) |
| "Proteinuria is biochemically represented by measuring the protein concentration in timed collection of 24 hour urine." | ( Ahmed, N; Arslan, MI; Asad, HB; Azad, K; Haque, MR; Mollah, FH; Rahman, MM; Wahab, MA, 2006) |
| "Detecting proteinuria is an integral part in management of hypertensive pregnant women." | ( Ciepłuch, R; Miśkiewicz, K; Preis, K; Skweres, T, 2006) |
| "Early proteinuria is associated with reduced long-term graft survival." | ( Al-Najjar, A; Buchler, M; Chatelet, V; Halimi, J; Houssaini, TS; Laouad, I; Lebranchu, Y; Nivet, H, 2006) |
| "Presence of proteinuria is considered as an early marker of an increased risk of progressive kidney disease." | ( Ahmed, I; Jacob, CK; John, GT; Kirubakaran, MG; Muliyil, J, 2006) |
| "An increase in proteinuria is linked with progressive renal failure." | ( Charbit, M; Dechaux, M; Gagnadoux, MF; Grünfeld, JP; Gubler, MC; Niaudet, P, 2007) |
| "Exercise-induced proteinuria is a common consequence of physical activity, although its mechanism is not clear." | ( Gündüz, F; Koçer, G; Kuru, O; Sentürk, UK, 2007) |
| "Proteinuria is the most important correlate of hypertension in CKD." | ( Agarwal, R, 2007) |
| "Proteinuria is associated with reduced kidney allograft survival." | ( Amer, H; Cosio, FG; Fidler, ME; Kremers, WK; Larson, TS; Morales, P; Myslak, M; Stegall, MD, 2007) |
| "Proteinuria is constituted by urinary albumin (UAE) and nonalbumin proteins (NAP)." | ( Al-Najjar, A; Chatelet, V; Halimi, JM; Laouad, I; Lebranchu, Y; Marlière, JF; Matthias, B; Nivet, H, 2007) |
| "Adriamycin-induced proteinuria is a well-established rat model for nephrotic syndrome." | ( Buikema, H; Navis, G; Ulu, N; van Gilst, WH, 2008) |
| "Exercise-induced proteinuria is a common consequence of physical activity and is caused predominantly by alterations in renal hemodynamics." | ( Gündüz, F; Koçer, G; Kuru, O; Sentürk, UK, 2008) |
| "As proteinuria is a risk factor for developing renal failure in future, routine screening of SCD patients is recommended for timely intervention in order to prevent or delay renal damage." | ( Aleem, A, 2008) |
| "Proteinuria is a well-established exacerbating factor in chronic kidney disease." | ( Fujita, T; Nagase, M; Shibata, S; Yoshida, S, 2008) |
| "Proteinuria is an important factor for renal injury and prognosis in many diseases." | ( Mir, S; Serdaroglu, E, 2008) |
| "Proteinuria is a common complication occurring after kidney transplantation." | ( Barama, AA, 2008) |
| "Because proteinuria is a major predictive factor of poor transplantation outcome, many studies focused on this adverse event during the past years." | ( Legendre, C; Letavernier, E, 2008) |
| "Proteinuria is a major long-term clinical consequence of diabetes and hypertension, conditions that lead to progressive loss of functional renal tissue and, ultimately, end-stage renal disease." | ( Barton, M, 2008) |
| "Persistent proteinuria is a major determinant of such progression." | ( Cattran, D; Philibert, D, 2008) |
| "Proteinuria is another very important risk factor for progression and its reduction (partial remission) improves the prognosis." | ( Ara, J, 2008) |
| "Hypertension and proteinuria are associated with severe histopathological findings." | ( Dusek, J; Groene, HJ; Janda, J; John, U; Misselwitz, J; Pohl, M; Seeman, T; Stejskal, J; Vondrák, K, 2008) |
| "Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality." | ( Chang, NC; Lee, TM, 2009) |
| "Proteinuria is associated with chronic kidney disease (CKD), and heavy proteinuria predicts a rapid decline in kidney function." | ( Benador, NM; Cole, SR; Furth, SL; Kaskel, F; Mak, RH; Pierce, CB; Schwartz, GJ; Warady, BA; Wong, CS, 2009) |
| "Proteinuria is associated with level of iGFR, cause of CKD, and race." | ( Benador, NM; Cole, SR; Furth, SL; Kaskel, F; Mak, RH; Pierce, CB; Schwartz, GJ; Warady, BA; Wong, CS, 2009) |
| "Proteinuria is an important diagnostic component of preeclampsia." | ( Hosseini-Asl, F; Shahbazian, N, 2008) |
| "Proteinuria is associated with progressive renal disease and overall mortality in HIV-infected patients; however, the prevalence and correlates of quantitative proteinuria in the highly active antiretroviral therapy era are unknown." | ( Bosch, RJ; Franceschini, N; Gupta, SK; Kalayjian, RC; Smurzynski, M; Szczech, LA, 2009) |
| "The amount of proteinuria is thought to increase in the early third trimester, irrespective of whether preeclampsia has been diagnosed." | ( Minakami, H; Morikawa, M; Yamada, T, 2009) |
| "Proteinuria is common after kidney transplantation and typically urine protein levels are below 500 mg/d." | ( Amer, H; Cosio, FG, 2009) |
| "Proteinuria is a major health-care problem that affects several hundred million people worldwide." | ( Mundel, P; Reiser, J, 2010) |
| "1." | ( Hennessy, A; Makris, A; Ogle, RF; Thornton, CE; Tooher, JM, 2010) |
| "The origin of proteinuria is found in either the glomerular filtration device or the proximal tubular reabsorption machinery." | ( Christensen, EI; Nielsen, R, 2010) |
| "Proteinuria is an increasingly recognized effect of sirolimus (SRL) therapy in kidney transplant recipients." | ( Augustine, JJ; Bodziak, KA; Hricik, DE; Padiyar, A, 2010) |
| "Hypertension and proteinuria are common but poorly understood renal toxicities of vascular endothelial growth factor (VEGF) receptor signaling pathway inhibitors." | ( Berlin, ST; Humphreys, BD; Ivy, P; Matulonis, UA; Penson, RT; Robinson, ES; Tyburski, K, 2010) |
| "Proteinuria is strongly associated with both the frequency and number of CMB in patients with recent cerebral ischemia." | ( Liebeskind, DS; Ovbiagele, B; Pineda, S; Saver, JL, 2010) |
| "Residual proteinuria is a strong modifiable risk factor for renal failure progression." | ( Ekhlas, A; Esnault, VL; Moranne, O; Nguyen, JM, 2010) |
| "Quantification of proteinuria is important in the assessment of chronic kidney disease (CKD)." | ( Deighan, CJ; MacGregor, MS; Methven, S; O'Reilly, DS; Traynor, JP, 2010) |
| "Proteinuria is a main feature of chronic renal disease and mediated by defects in the glomerular filtration barrier and is as a good predictor of cardiovascular events." | ( Barton, M, 2010) |
| "While proteinuria is considered as a marker of kidney function, albuminuria indicates cardiovascular risk first of all." | ( Anna, VO; Fodor, B; Horváth, A; Mátyus, J; Sárkány, E, 2010) |
| "Hypertension and proteinuria are commonly observed side-effects for anti-angiogenic drugs targeting the VEGF pathway." | ( Beijnen, JH; Gupta, A; Huitema, AD; Jansen, M; Karlsson, MO; Keizer, RJ; Mac Gillavry, MR; Schellens, JH; Wanders, J, 2010) |
| "Proteinuria is a major determinant of chronic kidney disease." | ( Kirk, GD; Lucas, GM; Mehta, SH; Vlahov, D; Yanik, EL, 2010) |
| "Sustained proteinuria is an important risk factor for not only renal but also cardiovascular morbidity and mortality." | ( Kawano, Y; Matsuoka, H; Miwa, Y; Ohta, Y; Sasaguri, T; Tominaga, M; Tsuchihashi, T; Ueno, M, 2010) |
| "Proteinuria is common in children and may represent a benign condition or a serious underlying renal disease or systemic disorder." | ( Leung, AK; Wong, AH, 2010) |
| "Proteinuria is common and is associated with adverse patient outcomes." | ( Deighan, CJ; Hair, M; MacGregor, MS; Methven, S; O'Reilly, DS; Traynor, JP, 2011) |
| "Proteinuria is associated with adverse cardiovascular and renal outcomes that are not prevented by current treatments." | ( Dhaun, N; Goddard, J; Haughie, S; Johnston, NR; Kerr, D; MacIntyre, IM; Melville, V; Webb, DJ, 2011) |
| "Decreasing proteinuria is the mainstay of therapy in order to delay the progression of CKD." | ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Measurement of proteinuria is of incremental prognostic benefit at every level of eGFR." | ( Bello, AK; Hemmelgarn, B; James, MT; Klarenbach, S; Lloyd, A; Manns, BJ; Tonelli, M, 2011) |
| "Proteinuria is the main indicator of renal disease progression in many chronic conditions." | ( Caletti, MG; Exeni, R; Grignoli, M; Missoni, M; Piantanida, JJ; Rasse, SM; Repetto, HA; Vezzani, C, 2011) |
| "Proteinuria is a diagnostic criterion frequently determined by albuminuria." | ( Allen, J; Knudsen, UB; Kronborg, C; Vittinghus, E, 2011) |
| "Proteinuria is the most sensitive marker of CKD progression in clinical practice, especially when combined with eGFR, but these have limitations." | ( Coombes, JS; Cooper, MA; Fassett, RG; Gobe, GC; Hoy, WE; Venuthurupalli, SK, 2011) |
| "Proteinuria is used as a predictor of outcome in severe illness and might correlate to systemic capillary leakage." | ( Beerthuizen, GI; de Leeuw, K; Eshuis, H; Janssen, WM; Niemeijer, AS; Nieuwenhuis, MK, 2011) |
| "Proteinuria is common following kidney transplantation and affects more than 40% of kidney transplant patients per year." | ( G-Cosío, F; Suárez Fernández, ML, 2011) |
| "Proteinuria is a strong predictor of adverse cardiovascular and kidney events, and an accurate assessment of proteinuria is important for the evaluation and management of CKD." | ( Upadhyay, A; Viswanathan, G, 2011) |
| "Heritable causes of proteinuria are rare and account for a relatively small proportion of all cases of proteinuria affecting children and adults." | ( Licht, C; Piscione, TD, 2011) |
| "Overt proteinuria is a strong risk factor for thromboembolism, owing to changes in the levels of various coagulation proteins and urinary antithrombin loss." | ( Kluin-Nelemans, HC; Laverman, GD; Mahmoodi, BK; Mulder, AB; Mulder, R; Navis, G; Slagman, MC; Spronk, HM; Ten Cate, H; Vogt, L; Waanders, F, 2011) |
| "Proteinuria is a common presentation of mesangioproliferative glomerulonephritis (MsPGN)." | ( Caglioti, C; Casoria, V; Comi, N; Conte, G; Fuiano, G; Fuiano, L; Iodice, C; Minutolo, R; Presta, P, 2011) |
| "Proteinuria is a common presentation of mesangioproliferative glomerulonephritis (MsPGN)." | ( Caglioti, C; Casoria, V; Comi, N; Conte, G; Fuiano, G; Fuiano, L; Iodice, C; Minutolo, R; Presta, P, 2011) |
| "Proteinuria is a common pathological finding in renal disease." | ( Cai, MM; Holt, SG; McMahon, LP; Smith, ER; Wright, DA, 2012) |
| "Proteinuria is an important risk factor for the progression and prognosis of chronic kidney disease." | ( Gan, W; Gong, J; Han, Y; Li, S; Zeng, Z; Zhang, A; Zheng, J, 2012) |
| "Proteinuria is an independent risk factor for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD)." | ( Ando, R; Fukami, K; Iwatani, R; Kaida, Y; Nakayama, Y; Okuda, S; Ueda, S; Yamagishi, S, 2012) |
| "However, proteinuria is a nonspecific marker of diverse forms of kidney injury, physiologic processes and filtration of small proteins of monoclonal and other pathologic processes." | ( Chowdhury, MA; Fukuda, A; Shedden, KA; Venkatareddy, MP; Wang, SQ; Wickman, LT; Wiggins, JE; Wiggins, RC, 2012) |
| "Proteinuria is considered to play an essential role in the progression of tubulointerstitial damage, which causes end-stage renal disease." | ( Cao, P; Ito, D; Ito, O; Joh, K; Kohzuki, M; Muroya, Y; Nakamura, Y; Rong, R; Takashima, K, 2012) |
| "Preoperative proteinuria is associated with a higher incidence of postoperative AKI." | ( Butrymowicz, I; Coca, SG; Garg, AX; Koyner, J; Molnar, AO; Parikh, CR; Patel, UD; Shlipak, M; Sint, K, 2012) |
| "Proteinuria is universal to all patients with preeclampsia." | ( Chen, G; Chen, J; Gu, Y; Jin, X; Niu, J; Zhang, L; Zhou, Y, 2013) |
| "Glomerular proteinuria is a hallmark of glomerular disease due to dysfunction of the filtration barrier." | ( Amann, K; Gessner, A; Goldwich, A; Steinkasserer, A, 2012) |
| "Proteinuria is associated with a shift of HDL size distribution towards large particles and cholesterol-poor HDL subclasses." | ( Bazán-Salinas, B; Carreón-Torres, E; Fragoso, JM; Franco, M; García-Sánchez, C; López-Olmos, V; Lorenzo, K; Madero, M; Pérez-Méndez, O; Posadas-Romero, C; Rodriguez-Pérez, JM; Soto-Miranda, E; Vargas-Alarcón, G, 2012) |
| "Proteinuria is an important cause of progressive tubulo-interstitial damage." | ( de Borst, MH; Hovingh, M; Kramer, AB; Kwakernaak, AJ; Mirković, K; Navis, G; Poosti, F; Sjollema, KA; Slagman, MC; van den Born, J; van Goor, H; Yazdani, S, 2012) |
| "To determine if proteinuria is more common in dogs with lymphoma when compared with healthy dogs and to assess the severity and frequency of proteinuria in dogs with lymphoma." | ( Cauvin, A; Di Bella, A; Maurella, C; North, SM; Schmidt, JM; Tapia, BB, 2013) |
| "Proteinuria is common in dogs with lymphoma, although in most cases it is not severe." | ( Cauvin, A; Di Bella, A; Maurella, C; North, SM; Schmidt, JM; Tapia, BB, 2013) |
| "Mild proteinuria is a common finding in dogs with lymphoma." | ( Cauvin, A; Di Bella, A; Maurella, C; North, SM; Schmidt, JM; Tapia, BB, 2013) |
| "Proteinuria is an independent risk factor for progressive renal diseases because it initiates or aggravates tubulointerstitial injury." | ( Ihoriya, C; Kadoya, H; Kashihara, N; Kidokoro, K; Nagasu, H; Nishi, Y; Sasaki, T; Satoh, M, 2013) |
| "Proteinuria is followed by podocyte injury." | ( Graziani, G; Ponticelli, C, 2013) |
| "Proteinuria is a common incidental finding in primary care." | ( Burkhalter, F; Dickenmann, M; Hirt-Minkowski, P, 2013) |
| "Proteinuria is associated with poorer outcomes in renal transplant recipients." | ( Clancy, MJ; Fox, JG; Geddes, CC; Jardine, AG; Methven, S; Patel, RK; Stevens, KK, 2013) |
| "Proteinuria is the cardinal sign of renal disease, therefore accurate identification of clinically significant proteinuria is essential to the diagnosis and management of kidney disease." | ( MacGregor, MS; Methven, S, 2013) |
| "Proteinuria is a major predictor for progression of renal disease, including diabetic nephropathy." | ( Chan, JC; Haneda, M; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T, 2013) |
| "Proteinuria is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors (mTOR-i)." | ( Guilbeau-Frugier, C; Guitard, J; Kamar, N; Roussel, M, 2014) |
| "Proteinuria is the main predictor of chronic kidney disease progression." | ( Lorenzo-Sellares, V; Ortiz-Arduán, A; Pérez-Gómez, MV, 2013) |
| "Proteinuria is a hallmark of many glomerular diseases and an independent risk factor for the progression of renal failure." | ( Berden, JH; Garsen, M; Rabelink, TJ; Rops, AL; van der Vlag, J, 2014) |
| "Proteinuria is the hallmark of renal disease." | ( Galesić, K; Kusec, R; Zivko, M, 2013) |
| "Proteinuria is an independent risk factor for renal graft loss." | ( Alonso, M; Borrego, J; Cabello, M; Castro, P; Gentil, MA; Mazuecos, A; Osuna, A; Pérez, MA; Rodríguez, A, 2013) |
| "Proteinuria is a major feature of lupus nephritis (LN) and reflects podocyte injury." | ( Bonfa, E; Borba, EF; Leon, EP; Malheiros, DM; Noronha, IL; Rezende, GM; Silva, C; Silva, NA; Viana, VS, 2014) |
| "Proteinuria is a common manifestation of renal disease." | ( D'Cruz, S; Kaur, R; Mundi, I; Punia, RP; Sachdev, A, 2014) |
| "Proteinuria is also a characteristic feature of hantavirus infections." | ( Aittoniemi, J; Huttunen, R; Libraty, D; Mäenpää, N; Mäkelä, S; Mustonen, J; Outinen, TK; Vaheri, A, 2014) |
| "Proteinuria is a simple sign of coexisting systemic inflammation due to NHL and a harbinger of a poor prognosis." | ( Ando, M; Hara, M; Maeda, Y; Nitta, K; Tsuchiya, K, 2014) |
| "Proteinuria is the most common clinical manifestation of glomerular diseases." | ( Huang, L; Wu, W; You, YS, 2014) |
| "Proteinuria is a marker of vascular dysfunction that predicted increased cardiovascular mortality and is associated with neurocognitive impairment (NCI) in population-based studies." | ( Clifford, DB; Currier, JS; Evans, S; Kalayjian, RC; Pallaki, M; Smryzynski, M; Wu, K, 2014) |
| "Proteinuria is the predominant risk factor for renal disease progression in Fabry disease (FD)." | ( Colomba, P; Duro, G; Pisani, A; Riccio, E; Sabbatini, M, 2015) |
| "Hypertension and proteinuria are important mediators of renal damage." | ( Bachtler, M; Bos, EM; Frenay, AR; Hillebrands, JL; Koning, AM; Kwakernaak, AJ; Leuvenink, HG; Navis, G; Pasch, A; Snijder, PM; van den Berg, E; van Goor, H, 2014) |
| "Proteinuria is not only a sign of kidney damage but is also involved in the progression of renal disease as an independent pathologic factor." | ( Ho, C; Hsu, YC; Lei, CC; Lin, CL; Shih, YH, 2015) |
| "Proteinuria is an independent risk factor for the progression of chronic kidney disease." | ( Cai, GY; Chen, XM; Deng, YY; Fang, JA; He, YN; Kou, J; Lin, HL; Nie, LF; Wu, J; Xie, YS; Yang, HT, 2014) |
| "The result of 24-h proteinuria is 2000 mg (667-4770) and baseline creatinine is 0." | ( Duque-Caballero, V; Márquez-Hernández, JD; Muñoz-Grajales, C; Pinto-Peñaranda, LF; Velásquez-Franco, CJ, 2015) |
| "Quantification of proteinuria is a fundamental step in staging dogs with chronic kidney disease and in monitoring the course of disease or the efficacy of anti-proteinuric treatments." | ( Bertazzolo, W; Binnella, M; Dondi, F; Gruarin, M; Paltrinieri, S; Rossi, G; Scarpa, P, 2015) |
| "Proteinuria is critical in the tubulointerstitial changes that ultimately lead to renal insufficiency." | ( Arnoni, CP; Boim, MA; Maquigussa, E; Pereira, LG, 2015) |
| "Proteinuria is a common manifestation of chronic kidney disease (CKD), and there is a high incidence of CDK and its complications following renal transplantation." | ( Chadimová, M; Dušek, J; Háček, J; Rosík, T; Seeman, T; Šimánková, N; Vondrák, K; Zieg, J, 2015) |
| "Proteinuria is an important cause of tubulointerstitial damage." | ( Dam, W; Hijmans, RS; Navis, G; Poosti, F; van den Born, J; van Goor, H; Yazdani, S, 2015) |
| "Posttransplantation proteinuria is associated with reduced graft survival as well as an increased risk of cardiovascular events and death." | ( Knoll, GA; Tsampalieros, A, 2015) |
| "Proteinuria is a dose-associated adverse event induced by anti-angiogenic agents; however, the mechanism mediating the induction of proteinuria by this type of agent remains largely unknown." | ( Fujisawa, M; Imai, S; Miyake, H, 2016) |
| "Persistent proteinuria is an important factor contributing to the progression of diabetic nephropathy." | ( Cai, G; Chen, X; Guan, X; Li, J; Li, W; Liu, M; Liu, W; Liu, Y; Lun, L; Wang, Y; Wu, H; Yao, H; Yin, S; Zhang, J; Zheng, Y; Zhou, C; Zhu, H; Zhuang, X, 2016) |
| "Proteinuria is an independent predictor for IgA nephropathy (IgAN) progression." | ( Liu, LJ; Lv, JC; Shi, SF; Zhang, H; Zhao, YF; Zhu, L, 2016) |
| "Proteinuria is the hallmark of clinical manifestation of disease activity in lupus nephritis (LN) patients, which arises from direct or indirect podocyte injury." | ( Jiang, W; Li, Z; Ma, R; Sun, Y; Wei, Z, 2016) |
| "Proteinuria is also now recognized as a common finding in individuals living with HIV." | ( Jones, R; Levy, JB; Milburn, J, 2017) |
| "Proteinuria is a common adverse effect of vascular endothelial growth factor targeted agents, particularly in metastatic renal cell carcinoma (mRCC)." | ( Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ, 2016) |
| "In conclusion, TA-proteinuria is confirmed as one of the best outcome indicators, also in patients with a severe renal insufficiency." | ( Corghi, E; De Silvestri, A; De Simone, I; Del Vecchio, L; Ferrario, F; Furiani, S; Pani, A; Pozzi, C; Santagostino, G; Sarcina, C; Terraneo, V; Tinelli, C; Visciano, B, 2016) |
| "Proteinuria is a common marker of kidney damage." | ( Anyabolu, AE; Anyabolu, EN; Chukwuonye, II; Enwere, O, 2016) |
| "Proteinuria is one of the potential renal adverse effects of deferasirox, and monthly follow-up for proteinuria is suggested by Food and Drug Administration and European Medicine Agency." | ( Bayhan, T; Gümrük, F; Karabulut, E; Küçüker, H; Tutal, AD; Ünal, Ş; Ünlü, O, 2017) |
| "Proteinuria is a hallmark of glomerular injury, and persistent proteinuria is associated with graft failure in kidney transplant patients." | ( Chang, Y; Min, DI; Shah, T; Yang, J, 2017) |
| "Proteinuria is one of the primary risk factors for the progression of chronic kidney disease (CKD) and has been implicated in the induction of endoplasmic reticulum (ER) stress." | ( Ask, K; Brimble, E; Carlisle, RE; Chahal, J; Dickhout, JG; Lu, C; Upagupta, C; Yum, V, 2017) |
| "Although proteinuria is usually benign in the form of transient or orthostatic proteinuria, persistent proteinuria may be associated with more serious renal diseases." | ( Barg, SS; Leung, AK; Wong, AH, 2017) |
| "Hypoalbuminemia or proteinuria is related to resistance to loop diuretics." | ( Amitani, K; Imura, H; Ishihara, S; Ishikawa, M; Kikuchi, A; Maruyama, Y; Nakama, K; Omote, T; Sato, N; Shimizu, W; Sone, M; Takagi, K; Takahashi, N; Tokuyama, H, 2018) |
| "Proteinuria is used as an indicator of FSGS disease activity, but its use as a clinical trial end point is not universally accepted." | ( Gipson, DS; Gipson, P; Kamil, ES; Komers, R; Kretzler, M; Massengill, SF; Nachman, PH; Oh, G; Perumal, K; Selewski, DT; Spino, C; Trachtman, H; Troost, JP; Tuller, S, 2018) |
| "Proteinuria is one of the characteristic adverse events by ramucirumab(RAM)plus paclitaxel(PTX)combination therapy for advanced gastric cancer." | ( Fujita, J; Furukawa, H; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Makari, Y; Mikami, J; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T, 2017) |
| "Proteinuria is a frequent finding in canine leishmaniosis and its quantification by the urine protein-creatinine ratio (UPC) is an important parameter in the staging of canine lesihmaniosis as presented by the LeishVet group." | ( Baneth, G; Chen, H; Kuzi, S; Mazaki-Tovi, M; Segev, G, 2018) |
| "Hypertension and proteinuria are characteristic adverse events of BV therapy." | ( Asakura, M; Houchi, H; Kontani, K; Kosaka, S; Motoki, T; Takahashi, K; Tanaka, H; Yamaguchi, K; Yokomise, H, 2018) |
| "Proteinuria is a common complication in adults with autosomal dominant polycystic kidney disease (ADPKD) and serves as a risk factor for progression." | ( John, U; Pohl, M; Seeman, T, 2018) |
| "Proteinuria is a marker of chronic kidney disease in dogs and a risk factor for increased morbidity and death." | ( Coleman, AE; Creevy, KE; Lourenço, BN; Meindl, AG, 2019) |
| "Proteinuria is associated with decreased biologic activity of FGF-23 and increased serum phosphate." | ( Ahn, C; Choi, KH; Chung, W; Han, SH; Jhee, JH; Kang, SW; Kim, H; Kim, SW; Nam, KH; Oh, KH; Park, J; Park, JT; Park, SK; Yoo, TH; Yun, HR, 2020) |
| "Proteinuria is an important marker and is closely related to the progressive decline of renal function." | ( Dai, R; Han, X; Liu, H; Shen, Q; Sun, L; Xu, H; Zhai, Y, 2019) |
| "Proteinuria is known to be associated with both kidney function deterioration and cardiovascular diseases." | ( Amano, H; Kawaguchi, Y; Kobayashi, S; Ogura, M; Terawaki, H; Yokoo, T, 2019) |
| "Proteinuria is a marker for cardiovascular diseases and all-cause mortality." | ( Fuchigami, H; Ishizuka, T; Kakei, M; Kato, M; Kawaguchi, R; Kuroda, Y; Matsumoto, M; Munakata, H; Nakamura, T; Nakayama, K; Noda, M; Sakai, N; Tanaka, T, 2019) |
| "Proteinuria is a variable that differentiates classes III from IV-G, being significantly higher in the second." | ( Brevis, L; Méndez, GP; Oddó, D; Vargas, S, 2019) |
| "Podocyte loss and proteinuria are both key features of human diabetic nephropathy (DN)." | ( Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA, 2020) |
| "Proteinuria is a quite frequent adverse event during cabozantinib treatment." | ( Bonadio, AG; Bottici, V; Cappagli, V; Comai, G; Egidi, MF; Elisei, R; Giannese, D; La Manna, G; Moriconi, D; Viola, D; Vischini, G, 2021) |
| "A basal level of proteinuria is about 30-100 mg/day, the upper limit of basal proteinuria does not exceed 150 mg/day which is considered non-pathology." | ( Maříková, A; Oulehle, K; Tesař, V; Vachek, J; Zakiyanov, O, 2020) |
| "A basal level of proteinuria is about 30-100 mg/day, the upper limit of basal proteinuria does not exceed 150 mg/day which is considered non-pathology." | ( Maříková, A; Oulehle, K; Tesař, V; Vachek, J; Zakiyanov, O, 2020) |
| "Proteinuria is a strong prognostic factor in IgA nephropathy (IgAN)." | ( Ai, Z; Huang, F; Yang, Q; Yu, X; Zhou, Q, 2020) |
| "Renal proteinuria is associated with promoted renal dysfunction and a shorter survival period in dogs with chronic kidney disease (CKD)." | ( Akabane, R; Miyagawa, Y; Miyakawa, H; Nagakawa, M; Ogawa, M; Sakatani, A; Takemura, N, 2020) |
| "Proteinuria is more pronounced in childhood with a history of LBW and HBW while LBW children are more prone to develop hypertension." | ( Asong, CM; Assob, JCN; Halle, MP; Kalla, GCM; Kaze, FF; Kowo, MP; Nansseu, JR; Nguefack, S; Nzana, V, 2020) |
| "eGFR and proteinuria are the most important markers for clinical assessment of kidney function." | ( Chandrasekaran, A; Gondil, VS; Gupta, KL; Jha, V; Kohli, HS; Kumar, V; Ramachandran, R; Rastogi, A; Rathi, M; Sood, A; Yadav, AK, 2021) |
| "Proteinuria is one of the most typical manifestations of kidney involvement in Systemic Lupus Erythematosus (SLE)." | ( Alessandri, C; Celia, AI; Cerbelli, B; Conti, F; d'Amati, G; Diomedi-Camassei, F; Leuzzi, V; Priori, R; Scrivo, R, 2021) |
| "Proteinuria is one of the most important prognostic factors causing progression in kidney disease." | ( Arslan, Ş; Aytekin, G; Baloğlu, İ; Çölkesen, F; Türkmen, K; Yıldız, E, 2021) |
| "Proteinuria is a recognized risk factor for progression of canine chronic kidney disease (CKD)." | ( Akabane, R; Miyagawa, Y; Miyakawa, H; Ogawa, M; Sakatani, A; Takemura, N, 2021) |
| "Proteinuria is a condition in which an excessive amount of protein is excreted in urine." | ( Kurdziałek, K; Lewińska, I; Tymecki, Ł, 2021) |
| "Proteinuria is one of the diagnostic criteria of preeclampsia (PE)." | ( Abdelazim, IA; Amer, OO; Karimova, B; Shikanova, S, 2022) |
| "Proteinuria is a common finding in dogs with leishmaniosis." | ( Cardoso, L; Leal, RO; Monteiro, M; Pereira da Fonseca, I; Prata, S, 2022) |
| "Monitoring proteinuria is important for the management of patients with cancer treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) inhibitors (VEGF/Ri)." | ( Baba, E; Funakoshi, T; Goto, T; Hamaguchi, T; Horimatsu, T; Kataoka, S; Matsubara, T; Mihara, Y; Mizukami, T; Muto, M; Nakamura, M; Nishikawa, Y; Tsuchihashi, K; Tsumura, T; Yanagita, M, 2022) |
| "High persistent proteinuria is not associated with clinical and biological variables reflecting kidney injury during the first month of life." | ( Bonsante, F; Gouyon, JB; Guignard, JP; Iacobelli, S; Trigolet, M, 2023) |
| "Because proteinuria is a sentinel marker of renal dysfunction, we assessed its role in predicting CA-AKI in patients undergoing PCI." | ( Fujiwara, W; Ishiguro, T; Ishii, H; Ishii, J; Izawa, H; Kiyono, K; Miyagi, W; Miyazaki, A; Naruse, H; Nishimura, H; Niwa, Y; Shimizu, S; Sobue, Y; Takahara, S; Ueda, S; Watanabe, E; Yamada, R, 2022) |
| "Proteinuria is a major manifestation of kidney disease, reflecting injuries of glomerular podocytes." | ( Hsieh, TB; Jin, JP, 2022) |
| "Proteinuria is an unfavorable clinical condition highly associated with a risk of renal and cardiovascular disease in chronic kidney disease (CKD)." | ( Chen, D; Chen, Y; Chi, H; Gan, C; Jiang, W; Li, Q; Qiu, J; Wang, M; Yang, H; You, H; Zhou, X, 2022) |
| "Amelioration of proteinuria is one of main treatment targets in patients with glomerulonephritis, yet the remission rates are suboptimal." | ( Abdelaziz, TS; Fayed, A; Hammad, H; Philips, MV; Shaaban, A, 2023) |
| "Proteinuria is associated with many glomerular diseases and a risk factor for the progression to renal failure." | ( Buijsers, B; de Graaf, M; Garsen, M; Gockeln, L; Hillebrands, JL; Kamps, JAAM; Krenning, G; Lamb, HJ; Maciej-Hulme, ML; Nijenhuis, T; Rabelink, TJ; Sol, M; Sonneveld, R; van den Born, J; van der Meer, RW; van der Vlag, J; van Kuppevelt, TH; van Raalte, DH, 2023) |
| "Proteinuria is one of the most common adverse events leading to the discontinuation of bevacizumab therapy." | ( Aoki, T; Asahi, K; Ikeda, T; Kudo, K; Murasato, F; Nihei, S; Yaegashi, M, 2023) |
| "Proteinuria is an independent risk factor for the progression of diabetic nephropathy (DN) and an imbalance in podocyte function aggravates proteinuria." | ( Cao, J; Lin, Y; Tang, X; Tang, Y; Wan, F; Yang, R; Zhang, H, 2023) |
| "However, some proteinuria is persistent." | ( Ji, B; Liu, J; Shen, Q; Xu, H; Yin, Y; Yu, J, 2023) |
| "Proteinuria is common in heart failure with preserved ejection fraction (HFpEF), but its biologic correlates are poorly understood." | ( Azzo, JD; Cappola, TP; Chang, CP; Chirinos, JA; Cohen, JB; Cvijic, ME; Dib, MJ; Ebert, C; Gan, S; Gordon, DA; Gunawardhana, K; Kammerhoff, K; Liu, L; Ramirez-Valle, F; Salman, O; Schafer, P; Seiffert, DA; Wang, Z; Zamani, P; Zhao, L, 2023) |
| Excerpt | Reference |
|---|
| "After discontinuation of the CS treatment, proteinuria gradually increased, reaching values similar to those in control nephrotic rats." | ( Itoh, H; Kokui, K; Nakamura, H; Yoshikawa, N, 1992) |
| "After ESWL treatment proteinuria and albuminuria are found." | ( Blech, M; Kallerhoff, M; Müller-Siegel, K; Ringert, RH; Scheler, F; Verwiebe, R; Wassmann, K; Weber, MH, 1991) |
| "The effect of enalapril in treating proteinuria appears therefore to be due to a specific intraglomerular action." | ( Coles, GA; Davies, M; Hillis, AN; Thomas, DM; Williams, JD, 1991) |
| "Thus, CAP was proved effective in treating proteinuria, and C-test might give us an information of its proteinuria-suppressing effect in an individual case." | ( Akiu, N; Kinoshita, Y; Obara, K; Ootaka, T; Saito, T; Sato, H; Seino, J; Tsunoda, K; Yamaguchi, Y; Yasujima, M, 1990) |
| "They found that in the course of treatment proteinuria did not change and glomerular filtration declined insignificantly." | ( Jáchymová, M; Knotková, V; Nĕmecek, K; Petrů, I, 1990) |
| "After stopping gold (penicillamine) treatment proteinuria reached a median maximum of 2." | ( Hall, CL, 1989) |
| "When patients with Graves' disease were treated with 131I, proteinuria measured by 24 h collections developed in 9 of 14 patients without pre-existing proteinuria and appeared to diminish in 4 patients in whom proteinuria had been present before treatment." | ( Amos, N; Hall, R; Lazarus, JH; McGregor, AM; Tomlinson, K; Weetman, AP, 1985) |
| "In similarly treated rats, proteinuria and glucosuria developed at the onset of tubular necrosis and disappeared when the tubules were completely relined by epithelium suggesting that they are due to diffusion of protein and glucose from interstitium into tubular fluid across the denuded basement membranes and that epithelial cells, under normal conditions, act as a barrier to diffusion of certain substances between the interstitium and tubular fluid." | ( Carone, FA; Ganote, CE; Peterson, DR, 1974) |
| "In addition, pulse treatments reduced proteinuria and urine sediment abnormalities in these patients." | ( Cole, BR; Robson, AM; Rose, GM, 1981) |
| "After this treatment, proteinuria of 100-300 mg/dl was continually observed throughout their life span, with pregnancy and delivery occurring 2-4 times." | ( Harbara, H; Hayashi, S; Kido, K; Mukai, M; Yamada, N, 1981) |
| "Drug treatment reduced proteinuria (by 70% and 36% at 28 and 48 weeks of age, respectively) plasma cholesterol (by 36% and 27% at 28 and 48 weeks of age, respectively) and prevented the decrease of plasma albumin observed in untreated rats (C-MNS) 48 weeks old." | ( Albertazzi, L; Calandra, S; Marchi, L; Nicolini, S; Salvati, P; Tarugi, P, 1994) |
| "At the end of the five-week treatment period, proteinuria, plasma urea and creatinine were measured and quantitative morphometry of the clipped and unclipped kidneys was performed." | ( Bruneval, P; Clozel, JP; Heudes, D; Ménard, J; Véniant, M, 1994) |
| "In the treatment group proteinuria was reduced from 8." | ( Böhler, J; Braun, N; Grupp, C; Heering, P; Schollmeyer, P; Zäuner, I, 1994) |
| "In untreated PAN rats, proteinuria reached a maximum at two weeks (271 +/- 38 mg/day)." | ( Fogo, A; Ichikawa, I; Kon, V; Tanaka, R; Yoshioka, T, 1994) |
| "Three years after the initiation of treatment, proteinuria and hematuria had significantly decreased in both groups, and the renal function in Group B was significantly improved." | ( Horigome, I; Hotta, O; Kurosawa, K; Sudo, K; Suzuki, K; Taguma, Y, 1993) |
| "Both treatments reduced proteinuria not only in hypertensive, but also in normotensive patients." | ( Huysmans, FT; Kloke, HJ; Koene, RA; van Hamersvelt, HW; Wetzels, JF, 1993) |
| "After treatment of CHF, proteinuria > 150 mg/24 h remained in 38% of group A and in none of group B." | ( Barretto, AC; Belloti, G; Bortolotto, LA; Galvão, LF; Pileggi, F; Silva, HB; Veloso, LG, 1993) |
| "In the course of the treatment, proteinuria disappeared or diminished and clinical improvement was seen in 21 patients." | ( Drozdz, D; Kwinta-Rybicka, J; Nowak, J; Sancewicz-Pach, K; Słowiaczek, E; Wilkosz, K, 1996) |
| "At the beginning of captopril treatment, proteinuria was 1633 +/- 666 mg/day." | ( Bar, J; Boner, G; Erman, A; Hod, M; Karp, M; Ovadia, J; Peled, Y; Rabinerson, D; van Dijk, DJ; Weintraub, N, 1995) |
| "Five years after the initiation of treatment, proteinuria was remarkably reduced from 1." | ( Chiba, S; Horigome, I; Hotta, O; Nishiyama, J; Oda, T; Sudo, K; Taguma, Y; Tomioka, S; Yoshizawa, N; Yusa, N, 1996) |
| "In vehicle-treated rats, proteinuria, glomerulosclerosis, interstitial mononuclear cell (MNC) infiltration and interstitial fibrosis developed." | ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1997) |
| "After 8 weeks of captopril treatment, proteinuria had decreased from 8 +/- 1." | ( Hernández, E; Morales, JM; Moreno, MA; Paz Artal, E; Praga, M; Rodicio, JL; Segura, J, 1997) |
| "After 20 days of treatment, proteinuria had only increased to 1,272 +/- 135 mg/kg/day, a reduction of 45% compared to the untreated control group (2,300 +/- 346 mg/kg/day; p < 0." | ( Hergenröder, S; Kirchengast, M; Münter, K, 1998) |
| "However, after 6 mo of Valsartan treatment, proteinuria was reduced by 396 +/- 323 mg/24 h (26 +/- 18%) and albuminuria by 531 +/- 499 mg/24 h (41 +/- 21%) with regard to baseline values (P < 0." | ( Bünten, B; Grabensee, B; Németh, R; Plum, J, 1998) |
| "During the treatment, proteinuria reduced in 5 patients, at less than 1/3 of pre-treatment values, for 4 patients this happened starting from the 2nd month of therapy, while after the 12th for the fifth patient." | ( Agliata, S; Airoldi, G; Cavagnino, A; Fortina, F; Ragazzoni, E; Sacco, A; Schweiger, K; Tommasini, G, 1999) |
| "In vehicle-treated rats, proteinuria, glomerulosclerosis, and interstitial fibrosis developed." | ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Naka, T; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1999) |
| "At variance in untreated rats, proteinuria showed a marked increase in the 10-week follow-up period (from 165 +/- 57 to 325 +/- 86 mg/24 hours)." | ( Bertani, T; Fassi, A; Perico, N; Remuzzi, A; Remuzzi, G, 1999) |
| "After 1 year of treatment, proteinuria significantly decreased in the corticosteroid group." | ( Hayashi, T; Hori, M; Imai, E; Nakanishi, I; Okada, N; Shoji, T; Suzuki, A; Togawa, M; Tsubakihara, Y, 2000) |
| "The failure of atRA treatment to reduce proteinuria could be due to the increase in TGF-beta1 levels and to inhibition of iNOS-driven NO production." | ( Datta, PK; Lianos, EA; Reddy, RS, 2001) |
| "At the start of treatment, median proteinuria was 744 mg/day (95% confidence interval (CI) 609-860) and plasma cholesterol was 10." | ( Bos, H; De Jong, PE; De Zeeuw, D; Henning, RH; Navis, G, 2002) |
| "Symptomatic treatment of proteinuria with losartan is therefore to be considered, especially with severe proteinuria even in normotensive patients." | ( Bilen, H; Cetinkaya, R; Odabas, AR; Selcuk, Y, 2001) |
| "Compared with vehicle treatment, statin treatment reduced proteinuria and renal injury independently of blood pressure and cholesterol concentrations in spSHRs." | ( Hirase, T; Hirata, K; Inoue, N; Kawashima, S; Miwa, Y; Namiki, M; Ozaki, M; Yamashita, T; Yokoyama, M, 2002) |
| "In RMR rats with no treatment, proteinuria progressively developed." | ( Aoki, M; Inagaki, O; Uchida, W; Yatsu, T, 2005) |
| "After the double-blind treatment phase, proteinuria was reduced to 1." | ( Delles, C; Fleischmann, EH; Klingbeil, AU; Schmieder, RE; Veelken, R, 2005) |
| "At the end of treatment, the mean proteinuria of the EAlow and EAhigh groups was significantly less than that of the vehicle group and no different from proteinuria at the onset of treatment." | ( Fan, F; Hoffmann, V; Lipsky, PE; Longo, NS; Tao, X, 2006) |
| "In conclusion, oral L-lysine treatment induced proteinuria, in particular albuminuria, as efficiently as previous reports on intravenous infusion." | ( Birn, H; Christensen, EI; Thelle, K; Vorum, H; Ørskov, H, 2006) |
| "Tacrolimus treatment reduced proteinuria and increased serum albumin (time effect, P = 0." | ( Chan, TM; Lam, MF; Tang, CS; Tang, SC; Tse, KC, 2007) |
| "At the start of treatment, proteinuria had progressively increased to 154 (95% confidence interval [CI]: 123-185) mg/24 h in the entire cohort, with comparable proteinuria and blood pressure in all groups." | ( de Zeeuw, D; Henning, RH; Hut, F; Jeronimus-Stratingh, CM; Kluppel, CA; van Dokkum, RP; Windt, WA, 2008) |
| "Combination treatment decreased proteinuria by 0." | ( Catapano, F; Chiodini, P; Conte, G; De Nicola, L; Gallo, C; Minutolo, R; Zamboli, P, 2008) |
| "In untreated MWF rats, proteinuria, hypertension, glomerulosclerosis, and renal function worsened, while lisinopril induced regression of both functional and structural changes." | ( Bonomelli, M; Condorelli, L; Conti, S; Gagliardini, E; Macconi, D; Remuzzi, A; Remuzzi, G; Sangalli, F, 2009) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "In adult aliskiren-treated rats proteinuria was significantly reduced compared with losartan (the effect persisting after withdrawal of treatment), and this decrease strongly correlated with normalization of glomerular size in these animals." | ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010) |
| "The degree of proteinuria at month 6 of treatment (residual proteinuria) and during follow-up (time-average proteinuria) showed a close relationship with renal end points." | ( Fu, BL; Hou, FF; Liang, M; Xie, D; Zhang, X, 2011) |
| "Further, carnosine treatment halved proteinuria and reduced vascular permeability to one-fifth in db/db mice." | ( Brismar, K; Forsberg, E; Gross, ML; Peters, V; Schmitt, CP; Zschocke, J, 2012) |
| "All patients failed steroid treatment, and mean proteinuria at the time of MMF initiation was 5." | ( Du, Y; Han, M; Hou, L; Wu, Y; Zhao, C, 2012) |
| "Total effective rate in treating proteinuria in high-dose group was 72." | ( Chen, XD; Li, X; Li, ZX, 2011) |
| "In NARs, PAN treatment induced proteinuria but not albuminuria and did not cause tubular damage, apoptosis, or lipid accumulation." | ( Cao, P; Ito, D; Ito, O; Joh, K; Kohzuki, M; Muroya, Y; Nakamura, Y; Rong, R; Takashima, K, 2012) |
| "Both groups responded well initially to treatment; proteinuria reduced to normal levels after 1 and 2 treatments in the normal and abnormal groups, respectively, while creatinine clearance returned to normal levels after 8 treatments in the abnormal group." | ( Dissaneewate, P; McNeil, E; Vachvanichsanong, P, 2013) |
| "Maximal treatment decreased proteinuria to 0." | ( Dikkeschei, BD; Dullaart, RP; Kwakernaak, AJ; Lambert, G; Laverman, GD; Navis, G; Petrides, F; Slagman, MC; Waanders, F, 2013) |
| "After MMF treatment, the proteinuria (p < 0." | ( Cheng, CC; Chiu, YT; Hsieh, TY; Lan, JL; Lee, YF; Lin, NN; Wang, JM; Wu, MJ, 2013) |
| "Post-treatment FSPF and proteinuria were measured." | ( Banks, M; Moudgil, A; Sgambat, K, 2013) |
| "After colchicine treatment, proteinuria was decreased in 12/15 patients in FMF_A group, however, the significant decreasing of proteinuria was not observed in RD_A group (p = 0." | ( Batgi, H; Ceri, M; Duranay, M; Guz, G; Inal, S; Ozturk, MA; Tuna, R; Unverdi, H; Unverdi, S, 2013) |
| "Currently, the treatment for proteinuria is mainly limited to angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs)." | ( Fu, P; Jordan, JB; Liu, F; Tu, X; Wang, F; Ye, XF; Zhong, S, 2013) |
| "Existing treatment of proteinuria is not sufficient to halt the chronic kidney disease (CKD) epidemic." | ( Balon, BP; Bevc, S; Ekart, R; Hojs, N; Hojs, R, 2013) |
| "Vitamin D receptor activator (VDRA) treatment reduces proteinuria, inflammation and fibrosis, but whether these effects depend on sodium intake has not been studied." | ( de Borst, MH; Frenay, AS; Mirkovic, K; Navis, G; van den Born, J; van Goor, H, 2017) |
| "Vitamin D treatment to reduce proteinuria remains controversial, although there is an inverse correlation between vitamin D levels and proteinuria." | ( Baltissen, MP; Berden, JH; Dijkman, HB; Ferrantelli, E; Florquin, S; Hoenderop, JG; Nijenhuis, T; Rops, AL; Sonneveld, R; Stavenuiter, AW; van der Vlag, J; Wetzels, JF, 2016) |
| "PVPA treatment reduced proteinuria and renal dysfunction induced by cyclosporine." | ( Chesnik, MA; Falck, JR; Hye Khan, MA; Imig, JD; Paudyal, MP; Sharma, A; Yeboah, MM, 2016) |
| "Our results showed that CsA and FK506 treatment decreased proteinuria via a mechanism associated to a reduction in the foot-process fusion and desmin, and a recovery of synaptopodin and podocin." | ( Bi, Y; Chen, J; Feng, S; Huang, X; Jiang, H; Lan, HY; Li, M; Li, X; Lin, C; Lin, W; Shen, J; Shen, X; Wang, H; Wang, L; Wang, Y; Weng, C; Xie, Z; Ying, M; Zhao, J; Zhou, J; Zhou, Q; Zhu, T, 2016) |
| "After the treatment, proteinuria disappeared in all patients at a median of 1." | ( Fujinaga, S; Hirano, D; Sakuraya, K; Satoshi, A; Yamada, A, 2018) |
| "Short treatment duration, lower pretreatment proteinuria than expected." | ( Aparicio, C; Bellasi, A; Cannata, A; Cozzolino, M; Ferrari, S; Kohan, DE; Lecchi, V; Mallamaci, F; Mazzaferro, S; Peraro, F; Perna, A; Perticucci, E; Remuzzi, G; Rotondi, S; Ruggenenti, P; Ruggiero, B; Tartaglione, L; Trillini, M; Tripepi, R; Villa, D; Zoccali, C, 2019) |
| "Aside effect of anti-angiogenic agent treatment is proteinuria." | ( Kitagawa, K; Masubuchi, M; Saito, Y; Sato, J; Watanabe, M; Yamamoto, H, 2019) |
| "Six dogs with pre-treatment proteinuria were treated with masitinib, significant worsening of proteinuria did not occur." | ( Helm, J; Kuijlaars, M; McBrearty, A, 2021) |
| "Use of telmisartan for the treatment of proteinuria in dogs has not been thoroughly investigated." | ( Fifle, L; Javard, R; Lecavalier, J, 2021) |
| "Telmisartan can be effective for the treatment of proteinuria in dogs." | ( Fifle, L; Javard, R; Lecavalier, J, 2021) |
| "Telmisartan can be considered for treatment of proteinuria in dogs, alone or in combination with other treatments for proteinuria." | ( Fifle, L; Javard, R; Lecavalier, J, 2021) |
| "Overall, there was a tendency of HCQ treatment to reduce proteinuria." | ( Mircescu, G; Stefan, G, 2021) |